Control Cohort CTRL COH

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05370079

Acronym

CTRL COH

Enrollment

350

Registered

2022-05-11

Start date

2023-08-08

Completion date

2028-08-08

Last updated

2026-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis

Keywords

Biological collection, control cohort,, new biomarkers

Brief summary

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.

Interventions

BIOLOGICALCollection of biological sample (blood and/or CSF)

Blood sample will be collected one time for each patient: 2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient with consent * patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.

Exclusion criteria

* refusal consent * patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis * patient under guardianship

Design outcomes

Primary

Measure	Time frame	Description
Samples (blood dry and EDTA tube and optional cerebro-spinal-fluid)	15 minutes	Numbers of samples collected and patients included in the cohort

Secondary

Measure	Time frame	Description
Description of genetic analysis	Data collecting: 3 years Data analysis: 2 years	Number of new biomarkers (genetic) and specific HLA (human leucocyte antigen)

Countries

France

Contacts

Primary ContactJerome Honnorat, Pr

jerome.honnorat@chu-lyon.fr(33) 4 72 35 78 06

Backup ContactGéraldine Picard, CRA

geraldine.picard@chu-lyon.fr(33) 4 72 35 58 42

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026